Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL

DOI: 10.1074/mcp.m111.013730
Molecular and Cellular Proteomics, 2012, 11, M111.013730.

#	Paper	IF	Citations
25	Investigation of stochasticity in TRAIL signaling cancer model. **2012**,		
24	The design and characterization of receptor-selective APRIL variants. *Journal of Biological Chemistry*, **2012**, 287, 37434-46	5.4	8
23	Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. *Cancer Research*, **2012**, 72, 4562-73	10.1	50
22	Structural data in synthetic biology approaches for studying general design principles of cellular signaling networks. *Structure*, **2012**, 20, 1806-13	5.2	13
21	Advancing cell biology through proteomics in space and time (PROSPECTS). *Molecular and Cellular Proteomics*, **2012**, 11, O112.017731	7.6	52
20	Death receptors as targets in cancer. *British Journal of Pharmacology*, **2013**, 169, 1723-44	8.6	135
19	Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. *British Journal of Cancer*, **2013**, 109, 2685-95	8.7	29
18	Systems biology of death receptor networks: live and let die. *Cell Death and Disease*, **2014**, 5, e1259	9.8	57
17	DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. *Cancer Biology and Therapy*, **2014**, 15, 1658-66	4.6	26
16	Multivalent interactions regulate signal transduction in a self-assembled Hg2+ sensor. *Journal of the American Chemical Society*, **2014**, 136, 11288-91	16.4	68
15	Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?. *Biochemical Pharmacology*, **2014**, 91, 447-56	6	45
14	Partial equilibrium approximations in apoptosis. II. The death-inducing signaling complex subsystem. *Mathematical Biosciences*, **2015**, 270, 126-34	3.9	3
13	TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. *BMC Cancer*, **2015**, 15, 494	4.8	17
12	Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma. *Journal of Investigative Dermatology*, **2016**, 136, 362-364	4.3	3
11	Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. *Oncogene*, **2016**, 35, 1261-70	9.2	45
10	Kinetic characterization of apoptotic Ras signaling through Nore1-MST1 complex formation. *Biological Chemistry*, **2017**, 398, 701-707	4.5	2
9	Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes. *Frontiers in Oncology*, **2018**, 8, 410	5.3	3

8	Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation. *Cancers*, **2019**, 11,	6.6	20
7	A New Efficient Method for Production of Recombinant Antitumor Cytokine TRAIL and Its Receptor-Selective Variant DR5-B. *Biochemistry (Moscow)*, **2019**, 84, 627-636	2.9	6
6	Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy. *Cancers*, **2019**, 11,	6.6	23
5	Death receptor 5 is activated by fucosylation in colon cancer cells. *FEBS Journal*, **2019**, 286, 555-571	5.7	14
4	Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 733688	5.7	3
3	Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. *Oncotarget*, **2018**, 9, 15566-15578	3.3	6
2	Two-level modeling approach to identify the regulatory dynamics capturing drug response heterogeneity in single-cells. *Scientific Reports*, **2021**, 11, 20809	4.9	0
1	Mass Action Kinetic Model of Apoptosis by TRAIL-Functionalized Leukocytes.		